However, on the other hand, it can be suggested that BCR/ABL1 fusion levels combined with CD56briCD38+ neutrophils count can hint the acceleration of blast cells in patients after CML treatment. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.